








Follow this and additional works at: https://tigerprints.clemson.edu/all_theses
This Thesis is brought to you for free and open access by the Theses at TigerPrints. It has been accepted for inclusion in All Theses by an authorized
administrator of TigerPrints. For more information, please contact kokeefe@clemson.edu.
Recommended Citation
Avudaiappan, Neela Saranya, "Data Mining in Large-Scale Clinical Visit Data for Rett Syndrome Patients" (2017). All Theses. 2728.
https://tigerprints.clemson.edu/all_theses/2728




the Graduate School of
Clemson University
In Partial Fulfillment











Rett syndrome (RTT) is a rare neurological disorder that predominantly affects girls. Re-
search on RTT has mostly centered around gene mutations and possibility of cure using gene therapy.
In this thesis we perform the first large scale systematic study of RTT patient records. The thesis
has two major goals. One is to identify behavioral groups and the other is to study the association
of medications and behavior or conditions. To achieve the first goal we apply standard clustering
techniques like non-negative matrix factorization and k-means. We identify behavioral groups which
could be used by clinicians for formulating better treatments. For the second goal we start with the
most popular existing technique, disproportionality analysis, and make necessary adaptations for
our data set. We then generalize this method and suggest an alternate approach which efficiently
answers which medication caused the most change in a behavior. We test both approaches and show
that the medications shown to decrease seizures the most are indeed those prescribed for the same.
Using this as a tool, clinicians can identify possible side effects of medications.
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Rett syndrome (RTT) is a neurobiological disorder that predominantly affects females and
was first described by Andreas Rett in 1960s. No cure has been found for Rett syndrome though
many medications and therapies improve the quality of the life of patients. Most of the research on
RTT has been on gene mutations and possibility of cure using gene therapy. No large scale systematic
study of RTT patient records to detect abnormalities, patterns, or prominent sub-populations with
consistent behavioral traits has been done to the best of our knowledge. A plethora of information
hidden in the medical records are underutilized which if used well could facilitate better treatment.
This is particularly true for non curable diseases where the only aim is to improve the standard of
life as much as possible and a better treatment would be a life long benefit for the patients. In this




RTT is a neurobiological disorder that is caused by mutations in MECP2 gene which is
located on the X chromosome at Xq28 [16]. Subjects are diagnosed to have either (1) classic / typical
RTT or (2) variant / atypical RTT. Atypical RRT is when the patient does not meet all diagnostic
criteria but has some symptomns of RTT. RTT is considered unique among other developmental
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disorders because of its “usually sporadic occurrence, extreme female gender bias, early normal
development and subsequent developmental regression, autonomic dysfunction, stagnation in brain
growth and distinctive neuropathology” [16]. The diagnostic criteria for RTT as per [21] is shown
in Table 1.1.
1.1.2 Medical Data Mining
The concept of storing health care data and information in electronic formats, now popularly
known as Electronic Medical Records (EMRs), dates back to early 1970s [6]. EMRs have facilitated
better viewing, ordering, care management, analysis, reporting and patient-directed functionality
[18]. One of the major uses of EMRs is in Safety Signal Detection which is defined by WHO as
detection of possible casual relationship between a drug and an adverse event. The Council for
International Organizations of Medical Sciences extended this definition to include beneficial events.
Adverse effects, often called “side effects” among non-health professionals are also known as Adverse
Drug Events (ADEs) or Adverse Drug Reactions (ADRs). Administrative health databases are
maintained by hospitals for administrative purposes and contain information on hospital admissions
and drug prescriptions. The major difference between these databases and EMRs if any is that EMRs
capture low level information on health care details of the patient. The branch of pharmacological
science that encompasses detection and assessment of adverse events is called pharmacovigilance [24].
Pharmacovigilance evaluates how safe a drug is by evaluating it after its release in the market, which
is referred to as postmarket surveillance. Passive surveillance relies on reports by health professionals
and manufacturers while active surveillance aims to automatically generate safety reports from
medical records and databases.
1.2 Related Work
Much of Rett-based research has been on gene mutations, studying involvement of MECP2
in biological, neurochemical and neurotransmitter/receptor systems. Notably, recent pre-clinical
studies on mouse models have indicated that the condition is potentially treatable [27]. Hence
most of Rett-based research now revolves around possible treatments like gene therapy, MECP2
reacivation, RNA editing and protein replacement. A large-scale study of patient records to analyze
patterns and clusters has never been done before.
2
Required for typical or classic RTT
Consider diagnosis when postnatal deceleration of head growth observed
Required for typical or classic RTT
1. A period of regression followed by recovery or stabilization
2. All main criteria and all exclusion criteria
3. Supportive criteria are not required, although often present in typical RTT
Required for atypical or variant RTT
1. A period of regression followed by recovery or stabilization
2. At least 2 of the 4 main criteria
3. 5 out of 11 supportive criteria
Main criteria
1. Partial or complete loss of acquired purposeful hand skills.
2. Partial or complete loss of acquired spoken language
3. Gait abnormalities: Impaired (dyspraxic) or absence of ability.
4. Stereotypic hand movements such as handwringing/squeezing, clapping/tapping, mouthing and wash-
ing/rubbing automatisms.
Exclusion criteria for typical RTT
1. Brain injury secondary to trauma (peri- or postnatally), neurometabolic disease, or severe infection
that causes neurological problems
2. Grossly abnormal psychomotor development in first 6 months of life
Supportive criteria for atypical RTT
1. Breathing disturbances when awake
2. Bruxism when awake
3. Impaired sleep pattern
4. Abnormal muscle tone
5. Peripheral vasomotor disturbances
6. Scoliosis/kyphosis
7. Growth retardation
8. Small cold hands and feet
9. Inappropriate laughing/screaming spells
10. Diminished response to pain
11. Intense eye communication - eye pointing
Table 1.1: RTT Diagnostic criteria reproduced from [21]
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Though data mining on patient records specific to Rett syndrome has never been done, work
on safety signal detection started in late 1970s. Most of the initial works were based on Spontaneous
Reporting Systems (SRSs). Spontaneous reports are reports with conclusions that a particular
drug may be responsible for an adverse event, drawn by clinicians during diagnostic appraisal of a
patient. While SRSs are reliable, they generally fail to detect most of ADEs because of duplication,
underreporting and reporting bias. A study in 1991 by A.P. Fletcher did a direct comparison between
event monitoring system and ADE reporting of over 44000 patients. He showed that under-reporting
could be as high as 98% for many ADEs. He argued that SRS suffered from reporting bias caused
by prejudices of medical staff, and other methods need to be explored to detect ADEs [3]. Though
the limitations of SRSs were discussed by Naranjo et al. [20] 10 years before Fletcher, no system
was introduced as an alternative until 1991. The first system that detected ADRs based on actions
recorded in patient records like decrease on dosage or discontinuation of medication was implemented
in 1991 by Classen [2]. The shortcomings of SRS have been studied many times hence (for example,
[1], [5] and [19]), in 2006 Joel Lexhin dicussed ways to improve quality and quantity of reporting
and argued that SRS would continue to play an important role in ADE detection.
The traditional method of detecting ADEs before EMRs was with chart reviews that were
prepared by nurses using patient data. In 2001 Honigman confirmed that computerized systems were
useful in detecting ADEs by comparing them with chart reviews and shifting to EMRs was valuable
[7]. Later in 2008 Hwang showed that computer based ADE monitoring was successful in identifying
most of ADRs with a study conducted in a 1300-bed tertiary care teaching hospital in Seoul, Korea.
Compared against a chart review by pharmacists to identify ADEs, the computer-based system was
shown to have 79% sensitivity and all severe ADRs were captured[11]. In 2009, Zhengwu Lu reviewed
the benefits, challenges and future of information technology in pharmacovigilance. He identified
that data mining signals were not always indicators of problems but were often good indicators of
possible problems. He concluded that data mining techniques could be used to improve efficiency of
pharmacovigilance and not replace it[15].
Through the years various statistical tests and data mining techniques were introduced for
ADE detection, most of which were based on Disproportionality Analysis (DA). The major methods
used were Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Yule’s Q ratio and
Information Component (IC). A study in 2002 compared these methods to detect ADRs on SRSs
on the Netherlands Pharmacovogilance Foundation Lareb dataset, and concluded that all methods
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were broadly comparable. They also highlighted the efficiency of IC in higher dimensions and for
large calculations [29]. Andrew et al. [30] recognized the exclusive use of disproportionality analysis
and listed other data mining techniques that could be useful in pharmacovigilance. Predictive mod-
eling, clustering, association mining and other visualization techniques were suggested as possible
techniques.
A year later Marc Suling and Iris Pigeot studied all data mining algorithms used in SRS
databases and how they can be extended for ADR detection in longitudinal databases. Other existing
algorithms for ADR detection in longitudinal databases are MUTARA and an improved version of it
called HUNTS [12]. Both approaches use Temporal Association Rules (TARs) to mine for patterns
as an extension of association rules. Noren et al. [22] proposed a method that extended DA in SRSs
to longitudinal patient records. In a time interval t, on drug of interest x, medical event of interest
y they define:
• ntx is the number of first prescriptions of x with follow up in time period t.
• nty is number of first prescriptions of any drug followed by y in time t.
• nt is the number of first prescriptions of any drug with follow up in time t.
• ntxy, is the number of first prescriptions of x followed by y in time t.












gives an association score that if positive can mean the event occurs disproportionately often and
if negative occurs disproportionately rarely. Noren et al. proposed the information component (IC)









which reduces sensitivity to outliers due to rare events using shrinkage. To account for temporal
variation they introduced IC∆. The follow up period of primary interest was u, and the control












Since these methods were implemented on different databases, it was hard to tell which
method was superior in ADR detection. A comparison of these algorithms was performed in [25]
and [26] on The Health Improvement Network (THIN) for six drugs with known adverse effects.
The conclusion of the study was that no algorithm was superior and all of them failed to detect rare
ADRs. The results indicated that HUNT could be more optimal when number of patients prescribed
the drug was small. The authors suggested that more than one algorithm must be used for ranking
ADEs. It was recently shown that disproportionality analysis in SRSs should be used for hypothesis
generation only and more robust methods were required to influence clinical decisions [17].
Apart from this, studies have been conducted to find correlation between clinical concepts
and laboratory test results. In 2011 George Hripcsak et al. [9] used lagged linear correlation to
reveal associations between clinical concepts extracted from sign-out notes and laboratory tests.
They found many interesting associations including low blood potassium preceding ‘hypokalemia’.
As an extension of their work, they used multivariate distributed lag models in their lagged linear
analysis. The addition of context-related variables was intended to facilitate better characterization
of intended and unintended effects [14]. Univariate lagged linear regression (ULLR) is used to
compute coefficients βτ , where yt represents laboratory value at time t and x represents drug value
at t− τ :
yt = ct + βτxt−τ + ε.
Multivariate lagged regression (MLLR) for L time lags and N variables is used to find βµi,τ , which

















The data sharing agreement between Greenwood Genetic Center and Clemson University
gave us access to 19 data files in the form of spreadsheets with medical records of patients with Rett
syndrome. As per the agreement the shared data had masked patient identification information and
replaced it with a unique maskid per patient. There were a total of 1194 patients involved in the
study. A brief overview of the documents is provided in Table 2.1. Along with the data files, data
dictionaries that contained a list of variable names, types and labels in the data files were provided.
2.2 Data Description and Preprocessing
The details of prescribed medications along with the indications for which it was prescribed
like cold, seizures etc., were maintained in two files. The details were maintained in the medicationlog
data file until a a point of time. The rest of the visits were recorded in the concomitantMeds file in a
different format. The medicationlog file contains 396 columns, the details of which are in Table 2.2.
This format assumes that a maximum of 49 medications would be prescribed on any visit. Patients
typically visited once every year or once every 6 months. On each visit the list of medications
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File No of fields length Details
adverseEvents 6 1 Has list of adverse events
childQuestionnaire 53 3971
Details of behavioral pattern filled out
parents on visits
clinicalCriteria 30 1225
Details on clinical criteria filled during
baseline visit
clinicalSeverityScale 16 6539
Details on clinical severity recorded ev-
ery visit
conclusionOfStudyParticipation 8 798
Details on when and why patients con-
cluded being a part of the study
concomitantMeds 1111 1016
Details on prescribed medications filled
during every visit in new format since
currenthistory 177 6545
Details on some clinical and behavioral
characteristics filled during every visit
deathrecord 22 61 Details on death of patients
demographicinfo 18 1225 Demographic information of patients
diagnosticmecp2status 28 1225 Details on diagnosis of patients
ekg 7 1614 Details of QT and QTc Intervals
eligibility 7 1228 consensus and Gene positive/negative
initialhistory 479 1213 Details on health during baseline visit
measurements 35 6557
Height, weight and other measurements
taken on every visit
medicationlog 396 2953 Prescribed medications in old format
motorbehavioralassessment 45 6531 Categorical details on behavior
registration 5 1234 Details filled during first registration
sf36 40 4381
Details of how patients felt about their
health
Table 2.1: Overview of data Files
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were entered one per column. The corresponding columns for indication, dose, etc., contains further
details. There are 49 columns, one for every medication.
• MedRxNormInput contains the name of the prescribed medication.
• Indication contains the condition for which the medication was prescribed.
• Units contains the units of the quantity of medication to be consumed if applicable.
• Frequency contains the frequency of medication like ‘once per day’, ‘AM;PM’ etc.
• Dose contains dosage of medication if applicable.
• Start age contains the age at which the medication was first prescribed.
• Stop Age contains the age when the patient stopped using the medication.
• MedRxCode contains the RxCode of the medication which is the code provided for each med-
ication by RxNorm.
RxNorm is a normalized naming system for many branded drugs and is provided by National
Library of Medicine (NLM) [23]. The name of the medication filled in MedRxNormInput contained
many errors. It was written in different formats, with different abbreviations, special characters,
and often contained spelling mistakes. This made the RxCodes a more reliable source to identify
medications, since they were free from any bias of medical practitioner. However, the MedRxCodes
field had many missing entries and other kinds of errors.
For example, the first two pairs of medications mentioned below are the same but have
different values in ‘code’ and other fields. To clean these and consider them the same medication
we only consider the concept unique identifier (CUI), i.e., C0875952 for Aciphex. We create a map
where we map CUIs with RxCodes such that the values are RxCodes that appear most number of
times for that CUI. The RxCodes do not have to be the error free; they only need to be the same for
all instances of same medication for our application. Using this technique, 204 unique medications
which were listed for a total of 841 times were corrected. Some entries have the CUI typed wrong
like the third pair below. These can be identified as the same using the “code”. Using this technique
32 unique drugs with 78 repetitions were cleaned. Other common errors included extra white spaces
like in the fourth pair. That can be easily solved by replacing all instances of more than one space
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with one space.
Aciphex [C0875952 code:261440 100.0 [RxNorm]
Aciphex [C0875952 code:RX10261440 100.0 [RxNorm]
Fiber [C0225326 code:70727 100.0 [RxNorm]
Fiber [C0225326 code:70727 95.0 [RxNorm]
Iron Supplement [217790] code:217790 100.0 [RxNorm R]
Iron Supplement [C0721124 code:217790 100.0 [RxNorm]
oxcarbazepine [C0069751 code:32624 100.0 [RxNorm]
oxcarbazepine [C0069751 code:32624 100.0 [RxNorm]
We only used codes to correct spellings and not standard techniques like edit distance. This
is because some drugs with low edit distance scores can be completely different and wrong inter-
pretations could cause serious discrepancies in the results. For example consider the following pairs
of drugs. Acetylcarnitine is a dietary supplement generally taken by patients with developmental
disorders while Acetylcysteine is a medication taken for cough.
Acetylcarnitine [C0001040 code:193 100.0 [RxNorm]
Acetylcysteine [C0001047 code:197 100.0 [RxNorm]
Sodium Chloride [C0037494 code:9863 100.0 [RxNorm]
Sodium Fluoride [C0037508 code:9873 100.0 [RxNorm]
Wafer [C0991560 code:316989 100.0 [RxNorm]
Water [C0043047 code:11295 100.0 [RxNorm]
In many cases the MedRxCode is unfilled and in some cases it is filled with name of med-
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Table 2.3: concomitantMeds fields
RxNorm does not provide codes for some nutritional supplements like “Children’s Multivitamin”,
“Gummy bears”, etc. To fill in the missing values for medicines that have RxCodes we used the
existing pairs of “MedRxNormInput” and “MedRxCode”. Such pairs can also be derived from the
concomitantMeds data file. We used this data to fill out most of the missing values. This also fixes
some misspelled medications if the error was already present in the data files. For the ones that
do not have RxCodes, we filled in our own code. For example for Ranitidine, the code generated is
Ranitdine [K35252627 code:35252627 100.0[RxNorm], we used ‘K’ instead of ‘C’ to distinguish the
legitimate RxCodes from those custom made.
In the concomitantMeds data file,
• conRMed contains the name of the medication.
• conRcode contains the RxCode.
• Conunits contains the units of medication like ‘milligram’.
• Confreq is the frequency at which the medication has to be taken.
• Conint contains the frequency of medications using medical terminology.
• Conroute contains how the medication needs be taken like “oral”, “inhaled”, etc.
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• ConContinuing indicates whether the medication is still used.
• ConDose is the dosage details.
• MoreThan3Months is true if the medication has been prescribed for more than three months.
• Conassess is the age the patients were at the assessment when the medication was recorded
in the database.
• Constart is the age the medication started.
• Constop is the age medication was stopped.
• ConSmed contains the indication.
• conScode contains the snomed code for the indication.
SNOMED CT (Systematized Nomenclature of Medicine Clinical Terms) or Snomed Clinical
Term provides codes, terms and definitions for medical terms that was introduced for improvement
of patient care [28].
While the medicationlog file’s rows correspond to visits, the concomitantMeds file’s rows
correspond to patients. That is, for each patient only one row / record is maintained and updated
on every visit. The start and stop of medication has to be inferred from Constart and Constop.
ConContinuing doesn’t have any meaning as it is modified on every visit and we only get to see the
last update. The other question is that of Constart and Constop: it is unclear how this representation
would capture a medication being prescribed on first and last visit but not in the intermediate
visits. To add to the challenge, most of Constart and Constop are unfilled, which makes even partial
assumptions invalid. Since using this file seemed to involve too many assumptions, we only used the
file in data cleaning of the medicationlog file.
One of the most interesting data files is childQuestionnaire since it is the only form filled
out by parents. It has rich behavioral information which is generally considered reliable. Parents
generally know the patients the most and convey information by daily observation over a period
of one or more years. But it could suffer from a reporter bias as different parents may understand
the scales differently. Unfortunately, the forms are not filled out on every visit and sometimes filled
out once every 2-3 years. Since this is a long gap, it becomes difficult to analyze if any medication
is causing behavioral changes using this form. The form contains mostly categorical data like (1)
13
Field Description
RateChildsHealth In general would you say your child’s health is
LimitedActivityLotOfEnergy
Doing things that take a lot of energy such as playing soccer or
running
LimitedActivitySomeEnergy Doing things that take some energy such as riding a bike or skating
LimitedActivityAbilityToGetAro
Ability physically to get around the neighborhood playground or
school
LimitedActivitySelfCare
Taking care of him/herself that is eating dressing bathing or going
to the toilet
EmotionalDifficultyKindsOfAction
Limited in the KIND of schoolwork or activities with friends
he/she could do
EmotionalDifficultyDurationOfA
Limited in the AMOUNT of time he/she could spend on school-
work or activities with friends
BehaviorInattentive Had difficulty concentrating or paying attention
BehaviorStealing Stole things inside or outside the home
MoodCrying Felt like crying
MoodLonely Felt lonely
MoodNervous Acted nervous
SatisfactionSchoolAbility His/her school ability
SatisfactionFriendships His/her Friendships
SatisfactionFamily His/her family relationships
RateChildsFutureHealth I expect my child will have a very healthy life
RateConcernForChildsPhysicalHe Your child’s physical health
LimitedByChildsPhysicalHealth Your child’s emotional wellbeing or behavior
FrequencyOfLimitationFamilyAct Limited the types of activities you could do as a family
FrequencyOfLimitationEverydayA
Interrupted various everyday family activities eating meals watch-
ing tv
FrequencyOfLimitationTensionCo Caused tension or conflict in your home
visit age Computed Age (in days) at visit (where DOB provided)
maskid Masked unique participant identifier
Table 2.4: some fields in childQuestionnaire
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Excellent, Very Good, Good, Fair, Poor, None, (2) Never, Almost Never, Sometimes, Fairly Often,
Very Often, (3) No, Not limited at all, Yes limited a little, Yes limited some, Yes limited a lot ranging
from scales 1-4, 1-5 or 1-6. Since the scales vary, it is important to normalize them before using
them for any machine learning. For our applications we do a min-max scaling where we make all
values range from 0-1 for techniques like non-negative matrix factorization where the values cannot
be negative, or standardize the data by making it zero mean, unit variance for methods like k-means.
This document also contains some missing values. If more than 50% of the rows are missing we do
not use it or if 50% or less values are missing we fill them by taking the average of previous and
next visit of the same patient if present. If it is the first visit we simply copy the value from the
next visit and if it is the last value we copy the previous visit value. The idea is to not fill in values
that will cause too much deviation. Another way of filling the missing values would be using mean
of field values of all visits for the particular patient.
Another document that contains some behavioral attributes and is filled out on every visit
is motorbehavioralAssessment. Though some information is clinical, it serves as a good pool of
information to study the effect of medications. The values are categorical with low values meaning
the patient is doing well. The scales are in the range 0-4 for every field. The missing values are filled
in a way similar to how childQuestionnaire file was filled.
Some of the most important details are contained in diagnosticmecp2status and demo-
graphicinfo. The diagnosis field in diagnosticmecp2status tells us if the patient is “classic”, “vari-
ant” or “non-rett”. Since we are are interested in analyzing Rett patients and the characteristics of
non-rett patients could be significantly different, we remove maskids of patients with diagnosis as
’non-rett’ in all our analysis. A similar role is played by “Gender” field in diagnosticmecp2status.
Since the characteristics of males with Rett is different and their count is negligible, we only analyze
female data. A total of 94 patients were found to fall under “non-rett” or “male” category. This is
not a huge number compared to 1193 unique patients found in the motorbehavioralAssessment file
for instance.
Since most of our analysis involved using more than one data file, we created one large
datafile that merged many data files to make clustering and other analysis easier. For all merges,
the visit was uniquely identified using maskid, visit age pairs. The tricky part is some of the files
have entries on every visit, some have entries on some visits and some only on baseline visit. The files

























































































Table 2.7: Fields in demographicinfo
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not change with time, like NormalInitialDevelopment, NormalPrenatalPeriod, etc. While merging,
we repeat the same values for every visit of the patient. But for the files where the entries were made
partially, like the childQuestionnaire, we leave them blank or fill in with a value like -1 to indicate
they were not filled. Apart from this, for studying effect of medication on behavior we merged
some fields of medicationlog and motorbehaviouralassessment using a left join. This is because the





The study of effect of medication on behavior is important in post-marketing pharmacovig-
ilance and has been done even before the advent of EMRs. In the following sections we show how to
adapt and extend popular approaches for this sort of association study, such as disproportionality
analysis (DA) and linear regression to our specific setting.
3.1 Disproportionality Analysis
3.1.1 Extensions to Consider Increases and Decreases
The most common method used for studying effect of medication is probably dispropor-
tionality analysis; for example, a recent work [22] discusses how to detect temporal patterns in
longitudinal patient records. To recall from Chapter 1, in a time interval t, on drug of interest x,
medical event of interest y we define:
• ntx is the number of first prescriptions of x with follow up in time period t.
• nty is number of first prescriptions of any drug followed by y in time t.
• nt is the number of first prescriptions of any drug with follow up in time t.
• ntxy, is the number of first prescriptions of x followed by y in time t.
• Etxy = ntx ·
nty
nt is the expected value of n
t
xy under a simple null model assuming no association
between x and y.
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Our goal is to study the effect of medication on behavior and clinical symptoms. To extend
this method to work on our dataset we need to define events based on change in behavior. The data
we have in motorbehaviouralassessment data file is on a scale of 1-4. Since we want to study if a
medication helps or exacerbates a condition, we define an event as increase in value which means
it has gotten worse and decrease in value which means it has gotten better. As per the algorithm,
we need to run it separately for (1) medication’s effect in increasing value of a behavior and (2)
medication’s effect in decreasing its value.
The natural way to define nty is as the number of increases / decreases. One major issue
with this is that we would be ignoring the scale of change by treating an increase by 1 and by 3 the
same. This would be underutilization of available data and might not produce desirable effects. We
will generalize our model to address this shortly, but for now we ignore the magnitude of change.
While the original algorithm considered a medical event of interest y, we now separately
consider two types of events y+ and y− that lead to the following terms.
• ntxy+ is the number of first prescriptions of x where the first subsequent change in behavior y
within time t is an increase.
• ntxy− is the number of first prescriptions of x where the first subsequent change in behavior y
within time t is a decrease.
• nty+ is the number of first prescriptions of any drug where the first change in behavior y within
time t is an increase.
• nty− is the number of first prescriptions of any drug where the first change in behavior y within
time t is a decrease.
• Etxy+ = ntx ·
nty+
nt
• Etxy− = ntx ·
nty−
nt
















Conveniently, the following theorem holds.
Theorem 3.1. At most one of IC+ and IC− can be positive.












































x, the LHS of (3.3) is 1, a contradiction.
As a cautionary remark, suppose we had defined a third type of event, y0 indicating a measurement
that indicates no change in behavior y. This would introduce two new terms:
• ntxy0 denotes the number of first prescriptions of x where the first subsequent measurement of
behavior y within time t indicates no change.
• nty0 denotes the number of first prescriptions of any drug where the first subsequent measure-
ment of behavior y within time t indicates no change.
Using these we can define IC0 just like IC− and IC+. However, while one can easily prove a
generalization of Theorem 3.1 that all three of these cannot be simultaneously positive, it is quite
possible for both IC+ and IC− to be positive (and we have observed this in our data). This is
clearly not desirable and we do not recommend extending the model to ternary events in this way.
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3.1.2 Extensions to Consider Magnitude of Increases and Decreases
Recall that the previous approach ignored the magnitude of change. To address this, we





They are now defined as the following:
• ntxy+ denotes the sum of magnitudes of all increases in behavior y occurring within time t
following any first prescription of x.
• ntxy− denotes the sum of magnitudes of all decreases in behavior y occurring within time t
following any first prescription of x.
• nty+ denotes the sum of magnitudes of all increases in behavior y occurring within time t
following any first prescription of any drug.
• nty− denotes the sum of magnitudes of all decreases in behavior y occurring within time t
following any first prescription of any drug.
Though this captures the change well, there is still an issue: both IC+ and IC− can be
positive if we are not careful in how we define Etxy+ and E
t
xy− via an appropriate null model. We
show this with a simple counter example.
Suppose there is an increase of 10 in behavior following one prescription of x and a decrease
of 10 following another. In addition, there is an increase of 1 and decrease of 1 in two cases where
















IC− = log2 1.909
Hence, both IC+ and IC− are positive. This, if not handled well could lead to seemingly
contradictory results. This can be fixed by checking if the value of nxy we get is significant by testing
it with the expected value of a slightly different, more nuanced null model. A null model is a model
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that is generated by randomizing the samples while preserving some of its statistical properties. The
null model we used so far was simplistic in assuming that x and y were unrelated.
Let us now calculate the expected value for ntxy+. There are n
t
x visits with first prescriptions
of x overall. Let us call these the x associated visits. The goal of our null model is to take each
individual increase in behavior (nty+ in total) and redistribute them. One way is to randomly shuffle
them such that the mass gets randomly distributed among all visits. In this case, the probability of
any value now being x associated would be nxnt as before. But in our new model, we would like to
preserve how much activity is present in x associated visits. An activity could mean an increase or a



















The overall activity after the first prescription of a medication is preserved in expectation
in this model. If a medication both increased and decreased a behavior a lot, the shuffling preserves
the activity and lands more positive mass there, thereby increasing the expected value. We use this
Etxy+ to calculate IC and we no longer get contradicting results. We get a proof similar to the one














xy−, and the LHS of (3.4) is 1, a contradiction.
Another potential issue is due to very low values of nx: if nxy is close to nx and there is
high increase/ decrease in those instances, the medication could have a high IC value thereby giving
false positives. This could result from rarely prescribed medications.
The adaptation of disproportionality analysis for our problem has some caveats that when
handled well could give us better results. To highlight, the main issues are
• DA considers effect of a medication on every behavior separately and hence does not give any
insight on possible interaction between drugs. For example the model does not capture the



















Table 3.1: Conditions affected the most by Keppra, a well known commonly prescribed seizure
medication
• It handles only binary events well.
3.1.3 Results from generalized DA
We have no standard way of knowing whether the method outputs reliable results other
than by using spot checks against results that would be anticipated based on strong clinical belief.
We first run our analysis and test if seizure medications have significant IC− values for decreasing
seizures.
The scatterplot in Figure 3.1 shows plot of the IC− values and nx values associated with
decrease in seizures. To get this list, a list of all unique medication names was generated, and
for each medication, IC− values for seizures was calculated. The plot in Figure 3.1 contains all
medications that have a positive IC−. A list of all seizure medications was retrieved using the
indications mentioned in the medicationlog data file and marked in the figure. There were a total
of 96 seizure medications and only 52 of which were prescribed for a total of 5 times or more. Out
of these, 42 seizure medications were found to have positive association with decrease in seizures.
Some of the false positives that seem to have high IC− values are the ones with very low n
t
x values
as seen in the plot. The reliable region is probably the one with higher ntx values where most of the
commonly used seizure medications like ‘Keppra’ lie. Another interesting observation is IC− values
for Myoclonus being high. Myoclonus is involuntary twitching of muscles and is related to seizures.
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Table 3.3: Conditions affected the most by Trileptal, another common seizure medication
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3.2 Linear Regression Model
3.2.1 Methodlogy
Disproportionality analysis considers every behavior and medication separately, and cannot
simultaneously test all medications affecting a behavior elegantly. It is also difficult to interpret
what the meaning of IC is. To address these and other issues discussed in the previous section, we
propose an unconstrained linear regression model. We define the following terms:
• b is a vector that represents change in behavior for all visits j.
• M is a matrix that contains values representing change in medication i in visit j.
• α and β are regularization parameters.
Our model assumes prescription of medication i results in change ai in the behavior under
consideration. Letting a be the vector of these values (the output we wish to compute), we would
like to ideally satisfy Ma = b; that is, we would like to be able to express the change in behavior on
each visit as precisely the linear combination of influences resulting from changes in medication at
that visit. The statement of the objective we need to optimize in order to best express a change in
behavior as a linear combination of medications is the following:
minimize
a
f(a) = ‖b−Ma‖22 + α‖a‖1 + β‖a‖22. (3.5)
In the above equation, for all non-initial visits, bj is the change in behavior on visit j
relative to visit j − 1. If lower values indicate being healthier, a negative difference would indicate
improvement in condition and vice versa. Mij can take one of three values 1, -1 or 0 depending on
whether a medication was introduced, removed or unchanged. “Introduced” means the medication
was not prescribed in visit j − 2 and prescribed in visit j − 1, “removed” means the medication was
prescribed in visit j − 2 and not prescribed in visit j − 1, and “unchanged” could mean two things
(1) medication was not prescribed in visit j − 2 and j − 1, or (2) medication was prescribed in visit
j − 2 and j − 1. Because of the way we have defined M , we ignore change of behavior in the first
visit of every patient. The regularization parameters α and β encourage sparsity and uniformity of
the resulting vector. To fully characterize the effect of changing values of these parameters on the
resulting vector is a challenging and deep question on its own, and left as a topic of future study.
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To calculate the gradient needed to minimize the function f , we simplify it:
f(a) = ‖b−Ma‖22 + α‖a‖1 + β‖a‖22
= (b−Ma)T (b−Ma) + α‖a‖1 + β‖a‖22
= bT b− 2bTMa+ aTMTMa+ α‖a‖1 + β‖a‖22
= bT b− 2bTMa+ aT (MTM + βI)a+ α‖a‖1.
(3.6)
We find the gradient as follows:
∇f(a) = −2bTM + 2(MTM + βI)a+ α · sign(a). (3.7)
The sign of ai tells us whether the medication i improved a behavior or made it worse. As
per our definition, a negative value of ai would indicate that the medication i helped in making
the condition get better and vice versa. A high absolute value would indicate that a particular
medication affected the behavior a lot. Because of this, there can be a better distinction of whether
a medication helps improve a condition or makes it worse.
One noticeable trait of a is its dependence on the scale of b in Equation 3.6. Normalization
of values might be better for some applications but for our purpose where the scales are even, we
prefer not to normalize. In our model, we consider Mij to be 0 when the medication i was prescribed
in both visit j − 2 and j − 1. This can be changed by assigning appropriate levels of values in case
of increase in dosage. We did not do this since the data on dosage we had seemed to be mostly
unfilled. The definition can also be changed based on whether the medication would have continued
effect throughout the prescription period.
The major drawback of our model can be said to be the following:
• We need a minimum of three visits to calculate effect of medication.
• We consider a change of behavior from 4 to 2 and from 2 to 0 as the same, which may not be
good.
• Assuming there is no effect when a medication continues to be prescribed.
26
3.2.2 Results
To check if our model produced reasonable results, we check if seizure medications helped
decrease seizures. Two seizure medications ‘Keppra’ and ‘Klonopin’ show up in the top five medi-
cations decreasing seizures in Table 3.4. In this setting we do not consider that a drug can continue
to have an effect if it is prescribed over a period of time. If we change that assumption and assign a
value of 0.4 to Mij when it was prescribed in both visit j−2 and j−1, we get slightly better results.
It could mean the medications continue to show effect over prescriptions or the dosage is a valuable
data that is missing. This time, three of the top five, and four of the top six medications are seizure
medications. The four seizure medications that show up in Table 3.6 are Keppra, Klonopin, Lamic-
tal and Topomax. The other medications that show up could possibly be the ones often prescribed
together with seizure medication, they can also be seen as the medications taken to suppress the
side effects of seizure medications. However, we have no data to back up this hypothesis and would
require a clinician to analyze it further. Another interesting observation is ‘Zantac’ and ‘Singulair’
showing up as medications that increase seizures in Tables 3.5 and 3.7 . ‘Zantac’ and ‘Singulair’
can produce dizziness and vertigo which could appear like fainting in a motor-impaired, non-verbal
subjects and interpreted as seizures. These are called non-epileptic spells and is indeed an issue with




Keppra [C0876060 code:261547 100.0 [RxNorm] -0.0325
ATROPINE @ 1% @ DROPS [C1353673 code:424405 100.0 [RxNorm] -0.0222
Klonopin [C0699315 code:202585 100.0 [RxNorm] -0.0194
Albuterol [C0001927 code:435 100.0 [RxNorm] -0.0164
Childrens Formula [C0719284 code:216009 91.4 [RxNorm] -0.0138
Table 3.4: Medications that helped decrease seizures the most
Medication a
Tegretol [C0700087 code:203029 100.0 [RxNorm] 0.0335
Singulair [C0595724 code:153889 100.0 [RxNorm] 0.0305
Zantac [C0592278 code:152523 100.0 [RxNorm] 0.0301
Benefiber, 100% oral powder for reconstitution [C1828775 code:686929 100.0 [RxNorm] 0.0277
Simethicone [C0037138 code:9796 100.0 [RxNorm] 0.0249
Table 3.5: Medications that increased seizures the most
Medication a
Keppra [C0876060 code:261547 100.0 [RxNorm] -0.1027
Klonopin [C0699315 code:202585 100.0 [RxNorm] -0.0668
Lamictal [C0678180 code:196502 100.0 [RxNorm] -0.0466
ATROPINE @ 1% @ DROPS [C1353673 code:424405 100.0 [RxNorm] -0.0434
Albuterol [C0001927 code:435 100.0 [RxNorm] -0.0432
Topamax [C0723778 code:220343 100.0 [RxNorm] -0.0357
Table 3.6: Medications that helped decrease seizures the most, assuming they have continued effect
Medication a
Prevacid [C0286036 code:83156 100.0 [RxNorm] 0.0674
Zantac [C0592278 code:152523 100.0 [RxNorm] 0.0638
Simethicone [C0037138 code:9796 100.0 [RxNorm] 0.0586
Singulair [C0595724 code:153889 100.0 [RxNorm] 0.0533
AQUAPHOR OINT,TOP C0715870 code:212929 100.0 [RxNorm] 0.0521




Patients with Rett syndrome are currently classified only at a very coarse-grained level as
classic or variant. While these are based on clinical criteria, patients show a huge variation in
behavior within each group. It is hence believed by many clinicians that identification of behavioral
groups could lead to better understanding of the nature of RTT as well as improved treatments.
For example, the techniques of the previous chapter could be applied to determine how effects of
medication vary across different subgroups, if at all. Our goal is to automatically discover natural
subpopulation of patients using the behavioral attributes in the childQuesstionnaire data file.
4.1 Non-Negative Matrix Factorization
Non-negative matrix factorization (NMF or NNMF) is a commonly used method in analysis
of high-dimensional non-negative data. Given a matrix X with non-negative entries, NMF factors
it into two non-negative matrices, W and H:
X = WH.
The problem is NP-hard in general but many heuristics exist to obtain reasonable solutions
in practice [4]. We use alternating non-negative least squares using projected gradients. NMF tends
to extract sparse and interpretable factors. In our data, X is a matrix with values of behavioral
attributes for each patient, where Xij ≥ 0 indicates the measured level in patient i of behavior j.
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Accordingly, the rows of output matrix W correspond to patients and H’s columns correspond to
behavior. The number of columns in W and rows in H, say k, is the number of clusters. The entry
Wir indicates the extent of membership of patient i in cluster r, and Hrj indicates the extent to
which cluster r is associated with behavior j. Note that, NMF provides a “non-crisp” partition
with data points being assigned multiple memberships. We assign a cluster to a patient based on
values in W and find the behavioral characteristics of the cluster by analyzing values in H. In our
application, we assign a patient the cluster of maximum value in W .
We cluster patients based on the first time point in the childQuestionnaire file. We perform
min-max scaling to normalize the data, so that all values are affinely mapped in the range [0, 1],
with 0 being minimum and 1 being maximum. Since we do not have any specific number of groups
to consider, we try different values of k and test using an alluvial diagram (Figure 4.1), if the
memberships change haphazardly. An alluvial diagram is a flow diagram that is typically used
to represent any change in grouping over time. In the alluvial diagram, we do not see anything
suspicious as the clusters are relatively consistent with different values of k. The group sizes are
uneven, and that could be because of how we assign membership. For example consider the following
row in W {0.582720202, 0.435967205, 0.357546551, 0.527948532, 0.1458655805}. Though group 4
has a value close to group 1, we assign the patient to group 1 because it has higher weight.
The values in H indicate the general behavior of the cluster. For example, the following are










The behaviors grouped together are quite related. The first group seem to have those who
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Figure 4.1: Alluvial diagram indicating how membership changes as the number of groups increases
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are not doing well with family activities, the second group can be seen as group with emotional
difficulty, the third group seems to be a group where parents (who fill out the questionnaire) are
very worried about the patient’s health, the fourth group seems to be physically less active. For
different values of k, the cluster characteristics remains well grouped as seen below.




2. LimitedByChildsBehavior(0.807689063063), LimitedByChildsAttention(0.766592208097), Fre-
quencyOfLimitationTensionCo(0.701325638214), FrequencyOfLimitationEverydayA(0.683725185299),
FrequencyOfLimitationCausingAr(0.680785371673)
3. RateWorryingOverChildsHealth(1.15449174153), RateChildsHealth2(1.09213101982), RateCon-
cernForChildsPhysicalHe(1.08609374692), RateConcernForChildsAttention(1.04416907966), Rate-
ConcernForChildsBehavior(1.02175899223)
















Prominent behaviors for k = 6:

















Prominent behaviors for k = 7:















6. RateChildsSeriousIllness(2.60416212182), RateChildsFutureHealth(1.16457190631), RateFre-
quencyOfPain(1.1368678442), RatePainOrDiscomfort(1.09371646958), RateChildsHealth(1.01064680601)
7. LimitedByChildsBehavior(1.06068369416), LimitedByChildsAttention(1.02275961415), Frequen-
cyOfLimitationEverydayA(1.00861980031), FrequencyOfLimitationTensionCo(0.986834948409),
FrequencyOfLimitationFamilyAct(0.936842896854)
While we have only looked at the high values, the low values can also be a valuable source
of information. This way of clustering patients can be useful to the clinicians who might use this
information to devise treatments and therapies.
4.2 K-Means Clustering
K-Means in one of the most popular clustering objective functions. When given a set of
points in d-dimensional space for a given k, the goal is to find k centers by minimizing squared
distance of every point to its closest center [13]. This problem is also NP-hard but a commonly used
heuristic approach usually finds reasonable solutions. The algorithm has two major parts, executed
in alternation until convergence:
• Assigning centers by finding mean of points in each cluster
• Updating membership of each point based on its closest center
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The most popular distance metric used is the Euclidean distance, which is well suited for
our application. This is because when two patients differ in some behavioral attribute by a larger
value we want their distance to be substantially higher. We standardize the data by making it zero
mean, unit variance. It is to be noted that this makes all coordinates contribute the same weight
to our distance calculation. This could be an issue if we use multiple data files for clustering where
one coordinate is split into several, thereby gaining extra weight just due to the extra level of detail.
A common way to overcome this issue is to use a weight vector in distance calculation using apriori
knowledge. Many recent methods suggest ways to automatically calculate weights [10].
An alluvial diagram shows that the patients remain well clustered even when clustered into
a different number of groups (Figure 4.2). An analysis of prominent behaviors in clusters reveal that
like NMF these clusters also show consistency across different values of k.
Prominent behaviors for k = 3:









Prominent behaviors for k = 4:










































































Analyzing the clusters, we notice the cluster centers are very similar to that of NMF. Con-
sidering k = 4 for example, the clusters have similar clinical interpretation as before. The first group
seems to be one where parents are very worried about patient‘s health, the second group can be
seen as group with emotional difficulty, third group has those who are not doing well with family
activities, and the the fourth group seems to be physically less active. The alluvial diagrams shows
that the clustering between NMF and k-means are similar. As k increases, NMF clusters become
more uneven causing more difference between the two methods. The left horizontal line indicates
NMF and the right one is for k-means in the following figures.
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Figure 4.4: Alluvial diagram showing relationship between NMF and k-means for k=3
Figure 4.5: Alluvial diagram showing relationship between NMF and k-means for k=4
40
Figure 4.6: Alluvial diagram showing relationship between NMF and k-means for k=5




In this thesis we had two major goals: (1) to study the effect of medications and (2) to iden-
tify behavioral clusters. We accomplished the first goal by using techniques like disproportionality
analysis and linear regression. Both the methods were reasonable in showing that seizure medi-
cations caused decrease in seizures. In both the methods, we considered any change in behavior
was an effect of medication only. A future work could be to include the effect of other therapies
and diets, also considering age as a factor that affects the effectiveness of medications. Another
interesting extension could be considering long term effects of using a medication, as our model
does not account for it. For our second goal we used techniques like NMF and k-means to cluster
patients using their behavioral characteristics. We showed that both methods have similar clusters
and the clusters were fairly stable when the number of clusters was changed. A future work could
use information on temporal change in behavior in clustering. Another interesting idea is to find
the effect of medications on behavioral groups.
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